JFG
INDV icon

Jefferies Financial Group’s Indivior Pharmaceuticals INDV Stock Holding History

Jefferies Financial Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
507,909
+21,083
+4% +$696K 0.11% 157
2025
Q4 		$17.5M Sell
486,826
-220,375
-31% -$6.73M 0.09% 211
2025
Q3 		$17.1M Sell
707,201
-1,483,073
-68% -$31M 0.08% 163
2025
Q2 		$32.5M Buy
2,190,274
+708,941
+48% +$8.26M 0.27% 79
2025
Q1 		$13.9M Sell
1,481,333
-153,770
-9% -$1.62M 0.12% 107
2024
Q4 		$20.9M Buy
1,635,103
+625,673
+62% +$6.44M 0.13% 124
2024
Q3 		$9.94M Sell
1,009,430
-129,081
-11% -$1.51M 0.07% 175
2024
Q2 		$17.9M Buy
1,138,511
+419,843
+58% +$7.58M 0.19% 89
2024
Q1 		$15.4M Sell
718,668
-853,011
-54% -$16M 0.14% 113
2023
Q4 		$23.7M Buy
1,571,679
+609,427
+63% +$10.8M 0.15% 93
2023
Q3 		$20.9M Buy
962,252
+375,711
+64% +$8.57M 0.19% 80
2023
Q2 		$13.6M Buy
+586,541
New +$13.4M 0.12% 154

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Financial Group's INDV Position: Q1 2026 in Review

Jefferies Financial Group increased its Indivior Pharmaceuticals (INDV) stake by 4.3% in Q1 2026, buying an estimated $696K and bringing the position to 507,909 shares worth $15.5M. The position accounts for 0.11% of the portfolio, ranked #157.

Jefferies Financial Group first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $32.5M in Q2 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Jefferies Financial Group held 507,909 shares of Indivior Pharmaceuticals worth $15.5M as of Q1 2026.
  • Jefferies Financial Group bought 21,083 Indivior Pharmaceuticals shares in Q1 2026, an estimated $696K.
  • Indivior Pharmaceuticals made up 0.11% of Jefferies Financial Group's portfolio in Q1 2026, its #157 holding.
  • Jefferies Financial Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Jefferies Financial Group's Indivior Pharmaceuticals position peaked at $32.5M in Q2 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.